Cover Image

Comparative Efficacy of Continuous Ceftazidime Infusion vs. Intermittent Bolus against In Vitro Ceftazidime-Susceptible and -Resistant <i>Pseudomonas aeruginosa</i> Biofilm

<b>Background</b>: As the anti-biofilm pharmacokinetic/pharmacodynamic (PK/PD) properties of antibiotics are not well-defined, we have evaluated the PK/PD indices for different regimens of ceftazidime (CAZ; with/without colistin) against <i>Pseudomonas aeruginosa</i> biofilm....

Full description

Saved in:

Bibliographic Details
Main Authors:	Cristina El Haj (Author), Eugènia Agustí (Author), Eva Benavent (Author), Laura Soldevila-Boixader (Author), Raül Rigo-Bonnin (Author), Fe Tubau (Author), Benjamín Torrejón (Author), Jaime Esteban (Author), Oscar Murillo (Author)
Format:	Book
Published:	MDPI AG, 2024-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by <i>Pseudomonas aeruginosa</i>
by: George L. Daikos, et al.
Published: (2021)

Genomic Analysis of Ceftazidime/Avibactam-Resistant GES-Producing Sequence Type 235 <i>Pseudomonas aeruginosa</i> Isolates
by: Raúl Recio, et al.
Published: (2022)

Bloodstream Infections Due to Wild-Type <i>Pseudomonas aeruginosa</i>: Carbapenems and Ceftazidime/Avibactam Prescription Rate and Impact on Outcomes
by: Carlo Pallotto, et al.
Published: (2024)

Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant <i>Pseudomonas aeruginosa</i> Bloodstream Infections and/or Hospital-Acquired Pneumonia
by: Milo Gatti, et al.
Published: (2022)

Evaluation of Ceftazidime/Avibactam Administration in Enterobacteriaceae and Pseudomonas aeruginosa Bloodstream Infections by Monte Carlo Simulation
by: Dai Y, et al.
Published: (2021)

Comparative Evaluation of Vitek 2 and Etest versus Broth Microdilution for Ceftazidime/Avibactam and Ceftolozane/Tazobactam Susceptibility Testing of <i>Enterobacterales</i> and <i>Pseudomonas aeruginosa</i>
by: Arhodoula Papadomanolaki, et al.
Published: (2022)

Ceftazidime/Tobramycin Co-Loaded Chitosan-Coated Zein Nanoparticles against Antibiotic-Resistant and Biofilm-Producing <i>Pseudomonas aeruginosa</i> and <i>Klebsiella pneumoniae</i>
by: Luís André de Almeida Campos, et al.
Published: (2024)

Comparative In Vitro Activity of Ceftazidime-Avibactam, Imipenem-Relebactam, and Meropenem-Vaborbactam against Carbapenem-Resistant Clinical Isolates of <i>Klebsiella pneumoniae</i> and <i>Pseudomonas aeruginosa</i>
by: Anthony Sophonsri, et al.
Published: (2024)

Population Pharmacokinetics and Probability of Target Attainment of Different Dosing Regimens of Ceftazidime in Critically Ill Patients with a Proven or Suspected <i>Pseudomonas aeruginosa</i> Infection
by: Annabel Werumeus Buning, et al.
Published: (2021)

Antimicrobial Synergy Testing: Comparing the Tobramycin and Ceftazidime Gradient Diffusion Methodology Used in Assessing Synergy in Cystic Fibrosis-Derived Multidrug-Resistant <i>Pseudomonas aeruginosa</i>
by: Ijeoma N. Okoliegbe, et al.
Published: (2021)

Suboptimal Concentrations of Ceftazidime/Avibactam (CAZ-AVI) May Select for CAZ-AVI Resistance in Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i>: In Vivo and In Vitro Evidence
by: Inmaculada Lopez-Montesinos, et al.
Published: (2022)

Susceptibility of Meropenem-Resistant and/or Carbapenemase-Producing Clinical Isolates of <i>Enterobacterales</i> (<i>Enterobacteriaceae</i>) and <i>Pseudomonas aeruginosa</i> to Ceftazidime-Avibactam and Ceftolozane-Tazobactam as Assessed by In Vitro Testing Methods
by: Venere Cortazzo, et al.
Published: (2022)

German Multicenter Study Analyzing Antimicrobial Activity of Ceftazidime-Avibactam of Clinical Meropenem-Resistant <i>Pseudomonas aeruginosa</i> Isolates Using a Commercially Available Broth Microdilution Assay
by: Jana Manzke, et al.
Published: (2022)

Mathematical pharmacodynamic modeling for antimicrobial assessment of ceftazidime/colistin versus gentamicin/meropenem combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm
by: Mona Shaban E. M. Badawy, et al.
Published: (2023)

In Vitro Evaluation of Increasing Avibactam Concentrations on Ceftazidime Activity against Ceftazidime/Avibactam-Susceptible and Resistant KPC-Producing <i>Klebsiella pneumoniae</i> Clinical Isolates
by: Marta Palombo, et al.
Published: (2023)

Levofloxacin-ceftazidime administration regimens combat Pseudomonas aeruginosa in the hollow-fiber infection model simulating abnormal renal function in critically ill patients
by: L Zhao, et al.
Published: (2020)

In Vitro Activity of Aztreonam-avibactam and Ceftazidime-avibactam against Pseudomonas aeruginosa Collected in a Global Surveillance Program in the Africa/Middle East, 2014-2017
by: I Morrissey, et al.
Published: (2020)

Combined Resistance to Ceftolozane-Tazobactam and Ceftazidime-Avibactam in Extensively Drug-Resistant (XDR) and Multidrug-Resistant (MDR) <i>Pseudomonas aeruginosa</i>: Resistance Predictors and Impact on Clinical Outcomes Besides Implications for Antimicrobial Stewardship Programs
by: Marianna Meschiari, et al.
Published: (2021)

Perbandingan Efektivitas Kombinasi Ceftazidime + Amikasin dan Ceftazidime sebagai Antibiotik Empiris Demam Neutropenia pada Keganasan
by: Agustinus William, et al.
Published: (2016)

Ceftazidime as an empiric therapy for neonatal sepsis
by: Indrayady Indrayady, et al.
Published: (2021)

Comparison of continuous epidural infusion and programmed intermittent epidural bolus in labor analgesia
by: Lin Y, et al.
Published: (2016)

Role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa
by: María José Contreras-Gómez, et al.
Published: (2022)

Evaluation of Aztreonam and Ceftazidime/Avibactam Synergism against <i>Klebsiella pneumoniae</i> by MALDI-TOF MS
by: Camila Mörschbächer Wilhelm, et al.
Published: (2023)

The <i>Klebsiella pneumoniae</i> carbapenemase (KPC) β-Lactamase Has Evolved in Response to Ceftazidime Avibactam
by: Sona Garsevanyan, et al.
Published: (2023)

Evaluation of Stability of Cefamandol and Ceftazidime with Clavulanic Acid Against Extended Spectrum Î²- Lactamase
by: Siham S. Shaokat, et al.
Published: (2017)

Analysis of the clinical application of ceftazidime-avibactam in China
by: Qing Wang, et al.
Published: (2022)

Synthesis of new derivatives of Ceftazidime as possible Prodrugs
by: Shakir M. Alwan, et al.
Published: (2017)

Synthesis of new derivatives of Ceftazidime as possible Prodrugs
by: Shakir M. Alwan, et al.
Published: (2017)

Ceftazidime-Avibactam Treatment for <i>Klebsiella pneumoniae</i> Bacteremia in Preterm Infants in NICU: A Clinical Experience
by: Andrea Marino, et al.
Published: (2023)

<i>Pseudomonas aeruginosa</i> Biofilm Formation, Infections and Treatments
Published: (2021)

Ceftazidime-Avibactam Therapy Versus Ceftazidime-Avibactam-Based Combination Therapy in Patients With Carbapenem-Resistant Gram-Negative Pathogens: A Meta-Analysis
by: Dan Li, et al.
Published: (2021)

In silico ADME and Toxicity Prediction of Ceftazidime and Its Impurities
by: Ying Han, et al.
Published: (2019)

Ceftazidime-avibactam induced renal disorders: past and present
by: Yanrong Shi, et al.
Published: (2024)

Resistance to Ceftazidime/Avibactam in <i>Klebsiella pneumoniae</i> KPC-Producing Isolates: A Real-Life Observational Study
by: Laura Campogiani, et al.
Published: (2023)

Ceftazidime-Avibactam in Combination with Imipenem as Salvage Therapy for ST11 KPC-33-Producing <i>Klebsiella pneumoniae</i>
by: Li Ding, et al.
Published: (2022)

Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature
by: Alessandro Mancuso, et al.
Published: (2023)

Absorption Kinetics of Subcutaneously Administered Ceftazidime in Hypoperfused Guinea Pigs
by: Tsuyoshi Ebihara, MS, et al.
Published: (2015)

Population pharmacokinetics and dose optimization of ceftazidime in critically ill children
by: Mengting Li, et al.
Published: (2024)

Biological and physicochemical stability of ceftazidime and aminophylline on glucose parenteral solution
by: Carolina Alves dos Santos, et al.
Published: (2012)

Treatment Heterogeneity in <i>Pseudomonas aeruginosa</i> Pneumonia
by: Aisling R. Caffrey, et al.
Published: (2022)